

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ACRUX DDS PTY LTD. & ACRUX LIMITED  
Petitioners

v.

KAKEN PHARMACEUTICAL CO., LTD. and  
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.  
Patent Owner and Licensee

---

Patent No. 7,214,506  
Issue Date: May 8, 2007  
Title: Method for Treating Onychomycosis

---

PETITION  
to Institute an *Inter Partes* Review of  
U.S. Patent No. 7,214,506  
*Under*  
*35 U.S.C. §§ 311-319 and*  
*37 C.F.R. § 42.100 et seq.*

Mail Stop PATENT BOARD  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
PO Box 1450  
Alexandria, Virginia 22313-1450  
*Submitted Electronically via the Patent Review Processing System*

## TABLE OF CONTENTS

TABLE OF AUTHORITIES .....	vi
EXHIBIT LIST .....	ix
I. A STATEMENT OF THE PRECISE RELIEF REQUESTED (§ 42.22(a)(1)).....	1
II. GROUNDS FOR STANDING (§ 42.104(a)) .....	1
III. MANDATORY NOTICES .....	2
IV. PAYMENT OF FEES (37 C.F.R. § 42.103).....	3
V. IDENTIFICATION OF CHALLENGES (§ 42.104(b)) .....	3
VI. SUMMARY OF THE '506 PATENT .....	5
A. Overview .....	5
B. The '506 Patent .....	5
C. Prosecution History .....	9
D. Challenged Claims of the '506 Patent.....	13
VII. EFFECTIVE FILING DATE OF THE CHALLENGED CLAIMS .....	14
A. The JP Priority Document Does Not Support Treating a Subject Having Onychomycosis .....	16
B. The JP Priority Document Does Not Disclose “topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound represented by the [chemical formula].” .....	18
C. The First Disclosure of the Claimed Elements was July 11, 2000 .....	19
VIII. APPLICABLE LAW AND LEVEL OF SKILL IN THE ART.....	20
IX. CLAIM-BY-CLAIM EXPLANATION OF GROUNDS FOR UNPATENTABILITY .....	21

A. Ground 1: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious Over Japanese Pat. App. Pub. No. 10-226639 in View of Ogura.....21

    i. JP ’639 Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound” .....22

    ii. Ogura Discloses the Antifungal Activities of Azolylamine Compounds Including KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....24

    iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine JP ’639 and Ogura to Arrive at the Method Recited in Claims 1 and 2.....25

B. Ground 2: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious Over U.S. Pat. No. 5,391,367 in View of Ogura.....30

    i. The ’367 Patent Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound” .....30

    ii. Ogura Discloses the Antifungal Activities of Azolylamine Compounds Including KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....31

    iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of the ’367 Patent and Ogura to Arrive at the Methods Recited in Claims 1 and 2. ....32

C. Ground 3: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious Over Hay in View of Ogura.....35

    i. Hay Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having

onychomycosis a therapeutically effective amount of an antifungal compound” .....35

ii. Ogura Discloses the Antifungal Activities of Azolyamine Compounds Including KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....36

iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine Hay and Ogura to Arrive at the Methods Recited in Claims 1 and 2. ....36

D. Ground 4: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious Over JP ’639 in View of the Kaken Abstracts .....40

i. JP ’639 Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound” .....41

ii. The Kaken Abstracts Disclose the Antifungal Activities of KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....41

iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of JP ’639 and the Kaken Abstracts to Arrive at the Method Recited in Claims 1 and 2. ....43

E. Ground 5: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious Over the ’367 Patent in View of the Kaken Abstracts. ....47

i. The ’367 Patent Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound” .....47

- ii. The Kaken Abstracts Disclose the Antifungal Activities of KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....47
- iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of the ’367 Patent and the Kaken Abstracts to Arrive at the Methods Recited in Claims 1 and 2.....48
- F. Ground 6: The Methods of Claims 1 and 2 of the ’506 Patent Would Have Been Obvious over Hay in View of the Kaken Abstracts.....51
  - i. Hay Teaches “a method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a therapeutically effective amount of an antifungal compound” .....51
  - ii. The Kaken Abstracts Disclose the Antifungal Activities of KP-103, *i.e.* a Compound Falling Within the Scope of the Claims .....51
  - iii. It Would Have Been Obvious to One of Ordinary Skill in the Art to Combine the Teachings of Hay and the Kaken Abstracts to Arrive at the Methods Recited in Claims 1 and 2.....52
- X. GIVEN THE OVERWHELMINGLY STRONG OBVIOUSNESS CASE, ANY EVIDENCE PATENTEE AND LICENSEE MAY OFFER RELATING TO SECONDARY CONSIDERATIONS IS NOT ADEQUATE TO OVERCOME THE FINDING THAT THE ASSERTED CLAIMS OF THE ’506 PATENT WOULD HAVE BEEN OBVIOUS AS A MATTER OF LAW .....55
  - A. The Alleged Unexpected Results of the Invention are Insufficient to Overcome the Strong Case of Obviousness Presented Herein .....57
    - i. The Alleged Unexpected Results Argued by Patentee During Prosecution were Actually Known Beneficial Results of the Use of KP-103 in the Treatment of Onychomycosis.....57

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.